The First European Symposium on Neurofibromatosis
The first European Symposium on Neurofibromatosis (NF) was sponsored by LINK, the British neurofibromatosis patients' association, and held over three days at the Runnymede Hotel, Egham, Surrey. The meeting was divided into two parts; the first was a scientific workshop devoted to laboratory studies of NF. This was attended not only by those actively working on NF but also by scientists working in related fields whose expertise brought fresh insights into ways of approaching NF The programme for the clinical meeting reflected the wide variety of specialists involved in the management of VRNF patients. Its aim was to inform the audience, drawn from an equally wide range of specialities, about the incidence and modes of presentation of the various disease complications, and the treatments available.
The session opened with two overviews of VRNF based on the findings of population studies: the recent South Wales study (Huson, Harrow) and the 39 year follow up of the patients originally identified by the study of Borberg (Mulvihill, Bethesda). The pathology of VRNF was then reviewed by Lantos (London), followed by Riccardi (Houston), who presented theories of pathogenesis and possible approaches to treatment. As neurofibromas are replete with mast cells and their development and growth is often associated with itching, he has assessed the use of the mast cell stabiliser ketotifen in controlling the pruritus and also the growth of large neurofibromas. The drug has only been used in a small number of patients but has been successful in controlling the pruritus; the results of growth control, however, were less conclusive.
A session on genetic counselling (Baraitser, London) followed. The difficulties in helping families come to terms with the uncertainties of long term prognosis and the cosmetic disfigurement caused by the disease were highlighted. Dr Baraitser was then joined by two LINK members who gave their personal experience of VRNF. Both had been frustrated by the lack of information about the disease and the numerous clinic visits to different specialists which were not coordinated. They felt that there was a clear need for other countries to follow the American example and establish neurofibromatosis clinics so that the patient always has one doctor taking an overview of the disease. Many VRNF sufferers do not receive genetic counselling and therefore are unprepared when their children develop complications when they had been told VRNF was just a 'skin problem'.
The programme then moved on to review the experience of different specialists in managing the complications of VRNF. These were: mental handicap and psychiatry (Samuelsson, Gothenburg), neurology (Hughes, London), oncology (Westbury, London), ophthalmology (Taylor, London), and plastic surgery (Poole, Oxford).
The only other form of NF reviewed at the meeting was BANF (Martuza, Boston 
